What is the ImmunityBio (IBRX) lawsuit about?

The lawsuit alleges ImmunityBio and its executives made false or misleading statements about the capabilities of its drug Anktiva, overstating its effectiveness. Investors claim these misstatements distorted the company’s outlook and caused financial losses when the truth emerged.

Why are investors suing ImmunityBio and Patrick Soon-Shiong?

Investors allege that Patrick Soon-Shiong and other executives misrepresented key facts about Anktiva and failed to disclose risks. These actions allegedly violated federal securities laws by misleading shareholders about the company’s business and prospects.

Who can join the ImmunityBio securities class action?

Investors who purchased ImmunityBio (NASDAQ: IBRX) securities and suffered financial losses may be eligible to join the class action. Those interested can also seek to be appointed lead plaintiff if they meet legal requirements before the filing deadline.

What is the deadline to become lead plaintiff in the ImmunityBio case?

The deadline to seek appointment as lead plaintiff in the ImmunityBio securities class action is May 26, 2026. Investors must act before this date to participate in a leadership role in the litigation.

What are the main allegations about ImmunityBio’s drug Anktiva?

The complaint claims Anktiva’s capabilities were materially overstated, giving investors an inaccurate picture of its potential. These alleged misrepresentations are central to claims that the company’s disclosures lacked a reasonable basis and misled the market.

ImmunityBio, Inc. - Faruqi & Faruqi LLP

ImmunityBio, Inc.

Join Action

Case Details

Ticker IBRX

Class Period 01/19/2026 - 03/24/2026

Lead Plaintiff Deadline 05/26/2026

Days Left to Seek Plaintiff

If you are a ImmunityBio investor who suffered a loss and would like to learn more, you can provide your information below:

If you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendant Patrick Soon-Shiong materially overstated Anktiva’s capabilities; and (2) as a result, defendants’ statements about ImmunityBio’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead Plaintiff Deadline: May 26, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

ImmunityBio, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify